Skip to content
The Policy VaultThe Policy Vault

Inqovi (decitabine and cedazuridine) — CareFirst (Caremark)

Myelodysplastic syndromes (MDS)

Initial criteria

  • Authorization may be granted for treatment of myelodysplastic syndromes (MDS).

Reauthorization criteria

  • Authorization may be granted for continued treatment when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

Approval duration

12 months